- /
- Supported exchanges
- / MX
- / BMY.MX
Bristol-Myers Squibb Company (BMY MX) stock market data APIs
Bristol-Myers Squibb Company Financial Data Overview
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane for the treatment of breast cancer. Further, it provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; and NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, specialty pharmacies, and to a lesser extent, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Bristol-Myers Squibb Company data using free add-ons & libraries
Get Bristol-Myers Squibb Company Fundamental Data
Bristol-Myers Squibb Company Fundamental data includes:
- Net Revenue: 48 194 M
- EBITDA: 19 116 M
- Earnings Per Share: 61
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-05
- EPS/Forecast: 1.2
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Bristol-Myers Squibb Company News
New
Does Colgate-Palmolive (CL) Blending Healthcare Expertise With a Measured Dividend Raise Reveal Its Strategic Priorities?
Colgate-Palmolive recently appointed Christopher S. Boerner, Ph.D., Chair and CEO of Bristol Myers Squibb, to its Board of Directors and modestly lifted its quarterly dividend to US$0.53 per share, ef...
Immatics N.V. (IMTX) Seeing Strong Enrollment in a Key Phase 3 Trial of Drug Candidate
Immatics N.V. (NASDAQ:IMTX) is among the best German stocks to buy according to analysts. On March 5, Immatics N.V. (NASDAQ:IMTX) reported its financial results for the year ended December 31. It also...
ImmunityBio Valuation: Paying 33x Sales for Anktiva
ImmunityBio’s IBRX stock has re-rated sharply as Anktiva transitions from a newly launched therapy to a product with accelerating prescriptions, expanding geographies, and active label-extension wor...
IBRX Stock: Anktiva's Approvals and What Comes Next
ImmunityBio IBRX has entered a new phase as a commercial-stage immunotherapy developer. The company’s near-term trajectory is closely tied to a single asset, Anktiva, which now anchors both revenue ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.